File(s) under permanent embargo
Further insight into the Heparin-Releasable and Glycosylphosphatidylinositol-lipid anchored forms of tissue factor pathway inhibitor
journal contribution
posted on 2023-05-16, 19:15 authored by Ellery, PER, Hardy, K, Oostryck, R, Adams, MJThe release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) was investigated using heparin and phospholipase C. The experiment included incubating HUVECs with 0, 1, or 10 U/mL heparin diluted in Dulbecco Modified Eagle's Medium plus 5% fetal calf serum for 1 or 24 hours. A statistically significant increase in TFPI activity levels was seen at 1 hour, but not at 24 hours. A 20-fold increase in the release of TFPI after phospholipase C treatment of HUVECs was demonstrated, confirming that it is glycosylphosphatidylinositol-lipid (GPI) anchored. Sequential treatment of HUVECs with phospholipase C and heparin was performed, and a trend was observed where GPI-anchored TFPI levels were increased after 1 hour of pretreatment with heparin but were decreased after 24 hours. Serum is a requirement for the heparin-dependent release of TFPI from HUVECs. Heparin pretreatment of HUVECs may affect levels of GPI anchored TFPI in a time and dose-dependent manner.
History
Publication title
Clinical and Applied Thrombosis and HaemostasisVolume
14Pagination
267-278ISSN
1076-0296Department/School
School of Health SciencesPublisher
Sage PublicationsPlace of publication
USARights statement
Copyright © 2008, Clinical and Applied Thrombosis/Hemostasis Online by SAGE PublicationsRepository Status
- Restricted